66.59 USD
↗ 7.71 (13.09%)AT CLOSE (11:59 AM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
66.60
↗ 1.41 (2.12%)
POST MARKET (AS OF 06:47 PM EDT)
Post Market
AS OF 06:47 PM EDT
66.60
↗ 1.41 (2.12%)
Market: OPEN
Open?$59.89
High?$70.22
Low?$59.29
Prev. Close?$58.88
Volume?1.1M
Avg. Volume?685.8K
VWAP?$65.99
Rel. Volume?1.64x
Bid / Ask
Bid?$56.45 × 100
Ask?$75.39 × 100
Spread?$18.94
Midpoint?$65.92
Valuation & Ratios
Market Cap?1.7B
Shares Out?28.7M
Float?17.1M
Float %?61.6%
P/E Ratio?N/A
P/B Ratio?45.49
EPS?-$0.46
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?9.07Strong
Quick Ratio?9.07Strong
Cash Ratio?6.17Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUED
Score33/100
P/E?N/A▾
P/B?45.49HIGH▾
P/S?7.22HIGH▾
P/FCF?86.3PRICEY▾
EV/EBITDA?30.0HIGH▾
EV/Sales?6.20HIGH▾
Returns & Efficiency
ROE?-35.6%WEAK▾
ROA?-3.6%WEAK▾
Cash Flow & Enterprise
FCF?$19.6M
Enterprise Value?$1.5B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295